FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses.
about
Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapyFingolimod for the treatment of neurological diseases-state of play and future perspectivesFTY720 reduces post-ischemic brain lymphocyte influx but does not improve outcome in permanent murine cerebral ischemiaMechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.Modulation of chemokines and allergic airway inflammation by selective local sphingosine-1-phosphate receptor 1 agonism in lungsFingolimod for relapsing multiple sclerosis: an update.Anti-inflammatory effects of FTY720 do not prevent neuronal cell loss in a rat model of optic neuritis.Fingolimod modulates microglial activation to augment markers of remyelination.Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS).AKP-11 - A Novel S1P1 Agonist with Favorable Safety Profile Attenuates Experimental Autoimmune Encephalomyelitis in Rat Model of Multiple SclerosisDiabetes tolerogenic vaccines targeting antigen-specific inflammationImmune modulating peptides for the treatment and suppression of multiple sclerosis.Fingolimod effects in neuroinflammation: Regulation of astroglial glutamate transporters?Potential of urinary metabolites for diagnosing multiple sclerosisNeuropathic pain in animal models of nervous system autoimmune diseases.G protein-coupled receptors as therapeutic targets for multiple sclerosis.Pharmacological inhibition of the chemokine receptor CX3CR1 attenuates disease in a chronic-relapsing rat model for multiple sclerosis.Roles for lysophospholipid S1P receptors in multiple sclerosis.FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination.The development of myelin repair agents for treatment of multiple sclerosis: progress and challenges.Extracellular cues influencing oligodendrocyte differentiation and (re)myelinationFTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system.Forced Exercise Preconditioning Attenuates Experimental Autoimmune Neuritis by Altering Th1 Lymphocyte Composition and Egress.Fingolimod reduces hemorrhagic transformation associated with delayed tissue plasminogen activator treatment in a mouse thromboembolic model.The sphingosine 1-phosphate receptor agonist FTY720 is neuroprotective after cuprizone-induced CNS demyelination.[Oral fingolimod in multiple sclerosis: therapeutic modulation of the sphingosine-1-phosphate system].Lipopolysaccharide Binding Protein and Oxidative Stress in a Multiple Sclerosis Model.[(11)C]DAC-PET for noninvasively monitoring neuroinflammation and immunosuppressive therapy efficacy in rat experimental autoimmune encephalomyelitis model.
P2860
Q27011473-41AF67A2-744C-4226-9BE3-D5A29E36BFF8Q27026175-4623B325-C140-4F4D-B7F5-DEE542F2555CQ28743446-A338A1BE-4BBE-475C-B098-0CE0785298CAQ33881977-7BB98626-1A64-44F2-BED8-861A2641C530Q34458426-6B08478C-D8F4-4837-B144-4CCBB80EB4C9Q34618474-B21D91D5-E389-4BBD-AF65-29451A50429BQ34805735-3FF14C25-5953-45C2-9E41-6F44A63D7DF2Q35154946-E4E3DDAD-D140-4F20-BB0A-3833EB995783Q35589934-E65A0CA8-53EA-45D5-A512-24EBD735BBE6Q35826151-696A2924-D6A8-4DF5-82C0-B873A88EF73AQ35887037-485E70BD-AA5F-40B9-8099-8A13ED96F7C7Q36151968-1C376B3D-0C05-4E64-A3A2-E050D18784CDQ36300679-559FA128-5974-488D-83E3-24510181C4EAQ36781267-919654DA-F503-4B80-8233-9F3B565421B5Q36869524-73C5FF78-379C-4E4C-AF54-330097B4D1F0Q37112554-2AD52726-9F22-43FC-BD91-7090D3404B4EQ37702072-D30C57FF-CEF8-4912-9372-94681D2548E0Q37803419-FAC48097-0D7C-447E-8A42-471EDDC57420Q37989903-D37A6B8F-BF20-4957-BE05-EFCB16164DE1Q38059361-A1E77F54-CD37-4DE4-85FF-583C5F5272CAQ38789322-08D1091F-12A3-4100-88B6-B420E12F657DQ39114974-4FF6ECFE-AF02-4D13-B30B-6519AB49C19CQ40723891-32C0C8D3-1AFE-4879-BC37-2D4DEAD25B60Q41659262-E7CA13FA-A258-4894-9612-ED82751187F6Q41958515-F0DCCED5-935E-4204-AC4E-5459C1D9EA22Q43838770-BD817EB2-9CD2-4F97-9A40-3BE0F586740DQ46480272-40F1BB08-72D0-45D8-A940-0AF35290F011Q53194305-E9D30ACA-307D-4A3E-85FE-0F28D9BCC3BB
P2860
FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
FTY720 ameliorates MOG-induced ...... and humoral immune responses.
@ast
FTY720 ameliorates MOG-induced ...... and humoral immune responses.
@en
FTY720 ameliorates MOG-induced ...... and humoral immune responses.
@nl
type
label
FTY720 ameliorates MOG-induced ...... and humoral immune responses.
@ast
FTY720 ameliorates MOG-induced ...... and humoral immune responses.
@en
FTY720 ameliorates MOG-induced ...... and humoral immune responses.
@nl
prefLabel
FTY720 ameliorates MOG-induced ...... and humoral immune responses.
@ast
FTY720 ameliorates MOG-induced ...... and humoral immune responses.
@en
FTY720 ameliorates MOG-induced ...... and humoral immune responses.
@nl
P2093
P2860
P356
P1476
FTY720 ameliorates MOG-induced ...... and humoral immune responses.
@en
P2093
Dimitrios Papadopoulos
Ian Marshall
Jennifer Stretton
Jill C Richardson
Jon Rundle
Karen L Philpott
Maria I Gonzalez
Rachel Eaton
Richard Reynolds
Ryan Patel
P2860
P304
P356
10.1002/JNR.22196
P577
2010-02-01T00:00:00Z